UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 294

Sortiert nach

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30, p.v485-v486

2019

Volltextzugriff (PDF)

Letter comments on: Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers

ESMO open, 2022-08, Vol.7 (4), p.100533-100533, Article 100533

2022

Volltextzugriff (PDF)

17 An audit comparing two different cisplatin schedules and subsequent nephrotoxicity for two different schedules used in concurrent chemoradiation: Sequential Or Concurrent Chemotherapy And Radiotherapy (SOCCAR) regime for inoperable non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2014, Vol.83, p.S7-S7

2014

Volltextzugriff (PDF)

63P A real-world comparison of the tolerability and toxicity of niraparib in older and younger women with high-grade serous ovarian carcinoma

ESMO open, 2024-06, Vol.9, p.103570, Article 103570

2024

Volltextzugriff (PDF)

1848P Managing hypersensitivity reactions in Ovarian malignancy – can we re-challenge successfully?

Annals of oncology, 2020-09, Vol.31, p.S1059-S1059

2020

Volltextzugriff (PDF)

11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts

Annals of oncology, 2022-04, Vol.33, p.S33

2022

Volltextzugriff (PDF)

11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.S43-S44

2023

Volltextzugriff (PDF)

716TiP DETERMINE: A pioneering UK precision medicine trial for rare cancers

Annals of oncology, 2023-10, Vol.34, p.S494-S495

2023

Volltextzugriff (PDF)

529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer

Annals of oncology, 2022-09, Vol.33, p.S788-S789

2022

Volltextzugriff (PDF)

927P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients

Annals of oncology, 2020-09, Vol.31, p.S667-S667

2020

Volltextzugriff (PDF)

EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC

Journal of thoracic oncology, 2022-09, Vol.17 (9), p.S395

2022

Volltextzugriff (PDF)

69TiP A pilot study of combined biomarker-based treatment strategies in patients with recurrent/metastatic squamous cell carcinoma of the cervix: RAIDS molecular targets trial for cervical cancer

Annals of oncology, 2020-10, Vol.31, p.S1238-S1238

2020

Volltextzugriff (PDF)

814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2020-09, Vol.31, p.S615-S616

2020

Volltextzugriff (PDF)

1031P - OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer

Annals of oncology, 2019-10, Vol.30, p.v421-v421

2019

Volltextzugriff (PDF)

OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer

Annals of oncology, 2019-10, Vol.30, p.v421

2019

Volltextzugriff (PDF)

1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30, p.v485-v486

2019

Volltextzugriff (PDF)

Small molecules that bind the Mdm2 RING stabilize and activate p53

Carcinogenesis (New York), 2012-04, Vol.33 (4), p.791-798

2012

Volltextzugriff (PDF)

1235 A phase-I study of the combination of intravenous reovirus (REOLYSIN ®) and gemcitabine in patients with advanced cancer

European journal of cancer supplements, 2009, Vol.7 (2), p.131-131

2009

Volltextzugriff (PDF)

Implications of BRCA1 and BRCA2 mutations on taxane sensitivity in patients (pts) with advanced ovarian cancer

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.5063-5063

2011

Volltextzugriff (PDF)

HER2 positive early breast cancers: tumour demographics and trastuzumab therapy in the real-world

Cancer research (Chicago, Ill.), 2009-01, Vol.69 (2_Supplement), p.3159

2009

Volltextzugriff (PDF)

A phase I study of the combination of intravenous Reolysin (REO) and gemcitabine (GEM) in patients (pts) with advanced cancer

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.3584-3584

2009

Volltextzugriff (PDF)

1031POCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

Unexplained seizure in anorexia nervosa

Canadian journal of psychiatry, 1986-10, Vol.31 (7), p.653

1986

Volltextzugriff (PDF)

Treatment of Persistent Phenothiazine-induced Oral Dyskinesia

British journal of psychiatry, 1970-03, Vol.116 (532), p.277-280

Roxburgh, Peter A.

1970

Volltextzugriff (PDF)

1 – 25 von 294

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(275)
Mit Volltextzugriff
(274)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(294)
Japanisch
(31)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Letter comments on: Glomerular filtration rate estimation for carboplatin dosing in patients with gynaecological cancers

17 An audit comparing two different cisplatin schedules and subsequent nephrotoxicity for two different schedules used in concurrent chemoradiation: Sequential Or Concurrent Chemotherapy And Radiotherapy (SOCCAR) regime for inoperable non-small cell lung cancer

63P A real-world comparison of the tolerability and toxicity of niraparib in older and younger women with high-grade serous ovarian carcinoma

1848P Managing hypersensitivity reactions in Ovarian malignancy – can we re-challenge successfully?

11P Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in second-line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts

11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors

716TiP DETERMINE: A pioneering UK precision medicine trial for rare cancers

529MO Phase II study of olaparib plus durvalumab with or without bevacizumab (MEDIOLA): Final analysis of overall survival in patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer

927P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected metastatic head and neck cancer patients

EP08.01-109 TACTI-002: A Phase II Study of Eftilagimod Alpha (Soluble LAG-3) & Pembrolizumab in 2nd line PD-1/PD-L1 Refractory Metastatic NSCLC

69TiP A pilot study of combined biomarker-based treatment strategies in patients with recurrent/metastatic squamous cell carcinoma of the cervix: RAIDS molecular targets trial for cervical cancer

814MO Phase II study of olaparib (O) plus durvalumab (D) and bevacizumab (B) (MEDIOLA): Initial results in patients (pts) with non-germline BRCA-mutated (non-gBRCAm) platinum sensitive relapsed (PSR) ovarian cancer (OC)

1031P - OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer

OCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer

1190PD - Phase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Small molecules that bind the Mdm2 RING stabilize and activate p53

1235 A phase-I study of the combination of intravenous reovirus (REOLYSIN ®) and gemcitabine in patients with advanced cancer

Implications of BRCA1 and BRCA2 mutations on taxane sensitivity in patients (pts) with advanced ovarian cancer

HER2 positive early breast cancers: tumour demographics and trastuzumab therapy in the real-world

A phase I study of the combination of intravenous Reolysin (REO) and gemcitabine (GEM) in patients (pts) with advanced cancer

1031POCTAVE: A phase I study of enadenotucirev, an oncolytic group B adenovirus, in combination with weekly paclitaxel in platinum-resistant epithelial ovarian cancer

1190PDPhase II study of olaparib + durvalumab (MEDIOLA): Updated results in germline BRCA-mutated platinum-sensitive relapsed (PSR) ovarian cancer (OC)

Unexplained seizure in anorexia nervosa

Treatment of Persistent Phenothiazine-induced Oral Dyskinesia

Suchergebnisse filtern